After this virtual tumor board, participants will be able to:

1. Understand how to select patients following resection of a primary GIST for adjuvant imatinib therapy
2. Recognize the options for managing primary GIST in difficult locations
3. Appreciate the approaches to imatinib-stable, metastatic GIST
4. Summarize the relationship of GIST mutational status with adjuvant systemic treatment selection
5. Recognize the indications for neoadjuvant systemic therapy for high risk GIST
6. Identify treatment options for patients with progression of metastatic disease

Ann Y. Lee, MD
Assistant Professor of Surgery
NYU Langone Health

Ronald P. DeMatteo, MD, FSSO, John Rhea Barton Professor and Chair, University of Pennsylvania

Emily Z. Keung, MD, AM, Assistant Professor of Surgery, The University of Texas MD Anderson Cancer Center

Ping Chi, MD, PhD, Medical Oncologist, Geoffrey Beene Junior Faculty Chair, Memorial Sloan Kettering Cancer Center